摘要
目的:探究灯盏花素注射液联合柴胡疏肝散用于早期肝硬化患者的临床疗效。方法:选择60例早期肝硬化患者随机分为观察组和对照组,各30例。对照组患者给予灯盏花素注射液治疗,观察组患者在对照组的基础上服用柴胡疏肝散治疗。比较两组患者治疗有效率及肝功能指标的变化。结果:观察组患者的总有效率为86.66%,明显高于对照组66.67%(P<0.05);治疗前,两组患者的谷丙转氨酶(glutamic-pyruvic transaminase,ALT)、谷草转氨酶(glutamic oxalacetic transaminase,AST)以及胆红素(bilirubin,TBIL)的水平差异无统计学意义(P>0.05),治疗后,两组患者的ALT、AST以及TBIL的水平较治疗前均降低,差异具有统计学意义(P<0.05)。结论:使用灯盏花素注射液联合柴胡疏肝散能够使患者的ALT、AST以及TBIL水平显著降低,明显优于单独使用灯盏花素注射液患者的临床治疗效果,使患者病痛减轻,提高治疗效果、促进预后。
Objective：To investigate the clinical efficacy of the combination of breviscapine and chaihu shugan powder on patients with cirrho-sis in early stage.Methods：60 cases of patients were randomly divided into the control group （30 cases） given breviscapine and the observation group （30 cases） given breviscapine combined with Chaihu Shugan powder.The effective rate of treatment and the change of liver function index were compared between the two groups.Results：The total effective rate in the observation group was significantly higher than that in the control group（86.66 % vs.66.67 %, P 〈0.05）.There was no significant difference in ALT, AST and TBIL between the two groups before treatment, but the level of ALT, AST and TBIL were significantly reduced in the two groups after treatment （ P 〈0.05）.Conclusion：Breviscapine combined with Chaihu Shugan powder can significantly reduce patients＆#39;level of ALT, AST and TBIL, which is obviously superior to breviscapine when it is solely used in therapy in the clinical therapeutic effect and which can alleviate patients＆#39;pain, enhance the curative effect and improve its prognosis.
出处
《包头医学院学报》
CAS
2015年第6期112-113,共2页
Journal of Baotou Medical College
